Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. Issue 8 (13th August 2021)

• Record Type: Journal Article
• Authors: Emens, Leisha A; Adams, Sylvia; Cimino-Mathews, Ashley; Disis, Mary L; Gatti-Mays, Margaret E; Ho, Alice Y; Kalinsky, Kevin; McArthur, Heather L; Mittendorf, Elizabeth A; Nanda, Rita; Page, David B; Rugo, Hope S; Rubin, Krista M; Soliman, Hatem; Spears, Patricia A; Tolaney, Sara M; Litton, Jennifer K
• Is Part Of: Journal for immunotherapy of cancer. Volume 9:Issue 8(2021)
• Publication Date: 2021-08-13
• Subjects: breast neoplasms -- guidelines as topic -- immunotherapy -- clinical trials as topic; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2021-002597
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Breast cancer has historically been a disease for which immunotherapy was largely unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with chemotherapy for the treatment of advanced/metastatic triple-negative breast cancer (TNBC) has demonstrated efficacy, including longer progression-free survival and increased overall survival in subsets of patients. Based on clinical benefit in randomized trials, ICIs in combination with chemotherapy for the treatment of some patients with advanced/metastatic TNBC have been approved by the United States (US) Food and Drug Administration (FDA), expanding options for patients. Ongoing questions remain, however, about the optimal chemotherapy backbone for immunotherapy, appropriate biomarker-based selection of patients for treatment, the optimal strategy for immunotherapy treatment in earlier stage disease, and potential use in histological subtypes other than TNBC. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew upon the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for breast cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence-based and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with breast cancer.